Galanthamine HBr

CAS No. 1953-04-4

Galanthamine HBr ( —— )

Catalog No. M13058 CAS No. 1953-04-4

Galanthamine hydrobromide is a long-acting, centrally active acetylcholinesterase(AChE) inhibitor (IC50 = 410 nM) and allosteric potentiator at neuronal nicotinic ACh receptors.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 32 In Stock
50MG 47 In Stock
100MG 56 In Stock
500MG 187 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Galanthamine HBr
  • Note
    Research use only, not for human use.
  • Brief Description
    Galanthamine hydrobromide is a long-acting, centrally active acetylcholinesterase(AChE) inhibitor (IC50 = 410 nM) and allosteric potentiator at neuronal nicotinic ACh receptors.
  • Description
    Galanthamine hydrobromide is a long-acting, centrally active acetylcholinesterase(AChE) inhibitor (IC50 = 410 nM) and allosteric potentiator at neuronal nicotinic ACh receptors.
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    AChR
  • Recptor
    AChE
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    1953-04-4
  • Formula Weight
    368.27
  • Molecular Formula
    C17H21NO3·HBr
  • Purity
    >98%(HPLC)
  • Solubility
    Water: 36 mg/mL (97.75 mM)
  • SMILES
    CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Thomsen T, et al. Eur J Clin Chem Clin Biochem, 1991, 29(8), 487-492.
molnova catalog
related products
  • Benzetimide hydrochl...

    Benzetimide hydrochloride is an antagonist of muscarinic acetylcholine receptor.treatment neuroleptic-induced parkinsonism.?

  • Gabapentin

    Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy.

  • Pirenzepine dihydroc...

    An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function.